ArticleClinical ophthalmology (Auckland, N.Z.)2026
Myopic and Astigmatic Laser in situ Keratomileusis Using a Ray Tracing-Based Treatment Algorithm with a Personalized Ablation Profile.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04219891 (Pivotal Trial of WaveLight® EX500 Excimer Laser System for the Correction of Myopia With and Without Astigmatism Using InnovEyes™ in Conjunction With InnovEyes™ Sightmap), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pivotal Trial of WaveLight® EX500 Excimer Laser System for the Correction of Myopia With and Without Astigmatism Using InnovEyes™ in Conjunction With InnovEyes™ Sightmap
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Evaluate the safety and efficacy of ray tracing‒based LASIK surgery to correct myopia in eyes with and without astigmatism. Patients and Methods: This prospective study included adults with myopia up to -10.00 D, with or without astigmatism (NCT04219891). For each eye, a 3D virtual model and personalized ablation profile were developed using data from InnovEyes™ Sightmap and ray-tracing algorithm, followed by a wavelight plus LASIK treatment. Efficacy endpoints included percentage of eyes achieving manifest refraction spherical equivalent (MRSE) within 1.00 and 0.50 D of emmetropia at refractive stability and uncorrected distance visual acuity (UDVA) assessments. Follow-up was up to 12 months. Safety endpoints included percentage of eyes that lost ≥2 lines corrected distance visual acuity (CDVA) at refractive stability versus preoperative CDVA and non‒flap-related ocular serious adverse events (SAEs). Mean optical aberrations were assessed. Dry eye symptoms were evaluated using ocular surface disease index scores. Patient-reported outcomes were assessed using Patient-Reported Outcomes With LASIK questionnaire. Results: A total of 163 patients (326 eyes) completed the study. Refractive stability was achieved at 3 months; during a 1- to 3-month interval, 99.4% of eyes had ≤1.00 D change in MRSE. MRSE within 0.50 and 1.00 D of emmetropia was achieved in 92.0% and 98.5% of eyes. At 12 months, 94.4% of eyes achieved UDVA of 20/20 or better. No eyes lost ≥2 lines of CDVA; no ocular SAEs or non-ocular adverse device effects were reported. Slight increase in coma (0.086 µm) and decrease in spherical aberration (-0.030 µm) were reported at 12 months. Dry eye symptoms improved after procedure (preoperative, 14.90±13.07; 12 months, 7.69±8.12). Postoperatively, 98% of patients reported being very/completely satisfied with their vision. Conclusion: Ray tracing‒guided LASIK treatment was safe and effective for correcting myopia in individuals with and without astigmatism, producing stable visual outcomes and high satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.